ArticleYonago acta medica2023

Clinical Outcomes of Switching from Zoledronic Acid to Denosumab for the Management of Severe Bone Metastasis from Hepatocellular Carcinoma: A Single-Center, Open-Label, Prospective Intervention Trial.

Kensuke Naruto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.